VIVUS to Present at Biotech Showcase on January 9, 2019
December 27 2018 - 7:30AM
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty
pharmaceutical company committed to the development and
commercialization of innovative therapies focusing on treatments
for patients with serious unmet medical needs, today announced that
John Amos, Chief Executive Officer, will present at the Biotech
Showcase™ 2019 on Wednesday, January 9, 2019 at 10:00am PT/1:00pm
ET. The conference will be held at the Hilton San Francisco Union
Square.
An audio webcast of the presentation will be available in the
events and presentations section of the Company’s website, or by
clicking here.
Biotech Showcase, produced by Demy-Colton and
EBD Group, is an investor and networking conference devoted to
providing private and public biotechnology and life sciences
companies with an opportunity to present to, and meet with,
investors and executives in one place during the course of one of
the industry's largest annual healthcare investor conferences, J.P.
Morgan Annual Healthcare Conference.
About VIVUS
VIVUS is a biopharmaceutical company committed
to the development and commercialization of innovative therapies
that focus on advancing treatments for patients with serious unmet
medical needs. For more information about the Company, please visit
www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as "anticipate,"
"believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should,"
among others. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. VIVUS does not undertake an obligation
to update or revise any forward-looking statements. Investors
should read the risk factors set forth in VIVUS' Form 10-K for the
year ended December 31, 2017 as filed on March 14, 2018, and as
amended by the Form 10-K/A filed on April 26, 2018, and periodic
reports filed with the Securities and Exchange Commission.
|
|
|
VIVUS,
Inc. |
|
Investor
Relations: Lazar Partners |
Mark Oki |
|
David Carey |
Chief Financial
Officer |
|
Managing Director |
oki@vivus.com
|
|
dcarey@lazarpartners.com |
650-934-5200 |
|
212-867-1768 |
|
|
|
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Sep 2023 to Sep 2024